These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

647 related articles for article (PubMed ID: 25534866)

  • 1. Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement.
    Zinellu A; Sotgia S; Mangoni AA; Sanna M; Satta AE; Carru C
    Nutr Metab Cardiovasc Dis; 2015 Feb; 25(2):153-9. PubMed ID: 25534866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease.
    Zinellu A; Sotgia S; Mangoni AA; Sotgiu E; Ena S; Satta AE; Carru C
    J Pharm Biomed Anal; 2016 Sep; 129():383-388. PubMed ID: 27454090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid-lowering therapy.
    Zinellu A; Sotgia S; Loriga G; Deiana L; Satta AE; Carru C
    Amino Acids; 2012 Oct; 43(4):1499-507. PubMed ID: 22278741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients.
    Zinellu A; Sotgia S; Sotgiu E; Assaretti S; Baralla A; Mangoni AA; Satta AE; Carru C
    Nutr Metab Cardiovasc Dis; 2017 Sep; 27(9):822-829. PubMed ID: 28755807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms.
    Schefold JC; Zeden JP; Fotopoulou C; von Haehling S; Pschowski R; Hasper D; Volk HD; Schuett C; Reinke P
    Nephrol Dial Transplant; 2009 Jun; 24(6):1901-8. PubMed ID: 19155537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer.
    Suzuki Y; Suda T; Furuhashi K; Suzuki M; Fujie M; Hahimoto D; Nakamura Y; Inui N; Nakamura H; Chida K
    Lung Cancer; 2010 Mar; 67(3):361-5. PubMed ID: 19487045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tryptophan degradation in multiple trauma patients: survivors compared with non-survivors.
    Ploder M; Spittler A; Schroecksnadel K; Neurauter G; Pelinka LE; Roth E; Fuchs D
    Clin Sci (Lond); 2009 Apr; 116(7):593-8. PubMed ID: 18986303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LDL S-homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy.
    Zinellu A; Sotgia S; Pisanu E; Loriga G; Deiana L; Satta AE; Carru C
    Eur J Pharm Sci; 2012 Aug; 47(1):117-23. PubMed ID: 22659373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum tryptophan and kynurenine concentrations as parameters for indoleamine 2,3-dioxygenase activity in patients with endometrial, ovarian, and vulvar cancer.
    de Jong RA; Nijman HW; Boezen HM; Volmer M; Ten Hoor KA; Krijnen J; van der Zee AG; Hollema H; Kema IP
    Int J Gynecol Cancer; 2011 Oct; 21(7):1320-7. PubMed ID: 21720257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease.
    Pawlak K; Domaniewski T; Mysliwiec M; Pawlak D
    Atherosclerosis; 2009 May; 204(1):309-14. PubMed ID: 18823890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute effects of fructose consumption on uric acid and plasma lipids in patients with impaired renal function.
    Zawiasa A; Nowicki M
    Metabolism; 2013 Oct; 62(10):1462-9. PubMed ID: 23866980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of electroconvulsive therapy on the tryptophan-kynurenine metabolic pathway.
    Guloksuz S; Arts B; Walter S; Drukker M; Rodriguez L; Myint AM; Schwarz MJ; Ponds R; van Os J; Kenis G; Rutten BP
    Brain Behav Immun; 2015 Aug; 48():48-52. PubMed ID: 25765557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue factor/its pathway inhibitor system and kynurenines in chronic kidney disease patients on conservative treatment.
    Pawlak K; Tankiewicz J; Mysliwiec M; Pawlak D
    Blood Coagul Fibrinolysis; 2009 Oct; 20(7):590-4. PubMed ID: 19491664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral kynurenine/tryptophan ratio is not a reliable marker of systemic indoleamine 2,3-dioxygenase: A lesson drawn from patients on hemodialysis.
    Chen Y; Xie Z; Xiao C; Zhang M; Li Z; Xie J; Zhang Y; Zhao X; Zeng P; Mo L; Liang X; Shi W
    Oncotarget; 2017 Apr; 8(15):25261-25269. PubMed ID: 28445957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased kynurenine plasma concentrations and kynurenine-tryptophan ratio in mild-to-moderate chronic obstructive pulmonary disease patients.
    Zinellu A; Fois AG; Zinellu E; Sotgiu E; Sotgia S; Arru D; Mangoni AA; Carru C; Pirina P
    Biomark Med; 2018 Mar; 12(3):229-237. PubMed ID: 29506391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does tryptophan degradation along the kynurenine pathway mediate the association between pro-inflammatory immune activity and depressive symptoms?
    Quak J; Doornbos B; Roest AM; Duivis HE; Vogelzangs N; Nolen WA; Penninx BW; Kema IP; de Jonge P
    Psychoneuroendocrinology; 2014 Jul; 45():202-10. PubMed ID: 24845191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Helicobacter pylori and serum kynurenine-tryptophan ratio in patients with colorectal cancer.
    Engin AB; Karahalil B; Karakaya AE; Engin A
    World J Gastroenterol; 2015 Mar; 21(12):3636-43. PubMed ID: 25834331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Posttransplant Tryptophan Metabolism Predicts Long-term Outcome of Human Kidney Transplantation.
    Vavrincova-Yaghi D; Seelen MA; Kema IP; Deelman LE; van der Heuvel MC; Breukelman H; Van den Eynde BJ; Henning RH; van Goor H; Sandovici M
    Transplantation; 2015 Aug; 99(8):e97-104. PubMed ID: 25651307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-invasive monitoring of kidney allograft rejection through IDO metabolism evaluation.
    Brandacher G; Cakar F; Winkler C; Schneeberger S; Obrist P; Bösmüller C; Werner-Felmayer G; Werner ER; Bonatti H; Margreiter R; Fuchs D
    Kidney Int; 2007 Jan; 71(1):60-7. PubMed ID: 17136028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia.
    Ohsawa M; Tamura K; Wakui H; Kanaoka T; Azushima K; Uneda K; Haku S; Kobayashi R; Ohki K; Haruhara K; Kinguchi S; Toya Y; Umemura S
    Lipids Health Dis; 2015 Dec; 14():161. PubMed ID: 26645467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.